Patrick O'Neil to Placebos
This is a "connection" page, showing publications Patrick O'Neil has written about Placebos.
Connection Strength
0.295
-
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018 08 25; 392(10148):637-649.
Score: 0.153
-
Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res. 2002 Jul; 10(7):633-41.
Score: 0.050
-
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022 01 11; 327(2):138-150.
Score: 0.049
-
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011 Jan; 19(1):110-20.
Score: 0.022
-
Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss. Obesity (Silver Spring). 2007 Apr; 15(4):895-905.
Score: 0.017
-
A controlled trial of naltrexone in obese humans. Int J Obes. 1985; 9(5):347-53.
Score: 0.004